Webcasts of Satellite Symposium from ESMO 2016

European Society for Medical Oncology

Progress in the treatment of advanced breast cancer: spotlight on selective CDK4&6 inhibitors

CDK inhibitors are emerging as a powerful treatment for advanced breast cancer. Progress in these treatments was discussed by a distinguished faculty of experts at a satellite symposium at this year’s ESMO congress, and the discussions, along with an interview with distinguished Chair of the symposium, Fatima Cardoso, are now available for you to view as a series of webcasts. Topics covered in the highly interactive symposium are:

  • The mechanisms underlying CDK4&6 inhibition
  • The rationale for using CDK4&6 inhibitors to treat advanced breast cancer
  • The clinical data supporting the use of CDK4&6 inhibitors in the treatment of advanced breast cancer.

 

Register for the E-Alert

About the speakers

Fatima Cardoso, MD

Fatima Cardoso is Director of the Breast Unit of the Champalimaud Clinical Center in Lisbon, Portugal.

Angelo Di Leo, MD, PhD

Angelo Di Leo is currently Head of the Sandro Pitigliani Medical Oncology Unit, and Chair of the Oncology Department, at the Hospital of Prato...

Naomi Fitzgibbon, Msc

Naomi Fitzgibbon is Cancer Information Service Manager at the Irish Cancer Society in Dublin, Ireland.

Lesley-Ann Martin, MD

Lesley-Ann Martin is Senior Staff Scientist and Group Leader within the Breast Cancer Now Tony Robins Research Centre...

Register for the E-Alert

Survey

We would like to know what challenges you face in treating patients with advanced breast cancer.

Send us your feedback and take this opportunity to submit your questions to our faculty.

Educational need

Clinicians have an unmet need to understand the mechanisms underlying CDK4&6 inhibition, the rationale for using CDK4&6 inhibitors to treat advanced breast cancer, and the clinical data supporting the use of CDK4&6 inhibitors in the treatment of advanced breast cancer.

Made possible by an educational grant from

Share